FOR IMMEDIATE Release
AgMedica Bioscience Inc. Holds First-Ever Multi-Therapeutic Stakeholder Roundtable
CHATHAM, ONTARIO – January 31, 2018 – In effort to begin to understand the needs of patients and the community organizations that represent them, AgMedica Bioscience Inc. is pleased to announce the completion of the first-ever Multi-Therapeutic Stakeholder Roundtable Meeting. This Roundtable Meeting, held in Toronto on Monday, January 15, 2018, aimed to bring discussion to the medicinal use of cannabis, in order to understand the unmet needs of multi-therapeutic patient communities.
Patient organizations that participated in the meeting included the Canadian AIDS Society, Epilepsy Canada, Canadian Organization for Retired People, Crohn’s and Colitis Canada and Brain Injury Association of Canada. “As a licensed producer of medical cannabis, it is incumbent upon us to truly understand the needs and concerns of those patients and communities we serve,” says Bruce MacEachern of AgMedica Bioscience. “By organizing a discussion whereby several community organizations were heard, we have taken the first step in establishing relationships in a sustained and efficient manner that will ultimately benefit those multi-therapeutic patients considering using medical cannabis.”
From a community perspective, engaging with companies like AgMedica through roundtables such as this only help serve the public interest around the responsible and safe use of cannabinoid therapies by patients. “Often times, there are little or no resources for patients who turn to medical cannabis,” says, Gary Lacasse, Executive Director, the Canadian AIDS Society. “We commend AgMedica for taking the initiative to reach out to community stakeholders and truly listening to ours and our constituents’ needs.”
“This is an excellent first step by AgMedica in engaging community stakeholders. Moving forward, we encourage AgMedica to expand beyond the participants from Roundtable in to other therapeutic areas, in order to encompass as many patients as possible,” adds Gary N. Collins, President of Epilepsy Canada.
AgMedica is a licensed producer under the ACMPR and is focused on the cultivation of quality, consistent medical-grade cannabis. The company’s Riverview Cultivation Facility is located in Chatham, Ontario. The Phase I Facility has an annual capacity of 6,000 kg of pharmaceutical-grade indoor cannabis. Plans are in place to expand this capacity within the existing building to 26,500 kg. The company is planning to begin cultivation in the coming weeks. The company’s second indoor facility is in the detailed review stage at Health Canada to become an ACMPR licensed producer and is forecast to add an additional 40,000 kg in annual capacity once fully built, providing AgMedica with a total projected indoor production capacity of 66,500 kg per year.
AgMedica’s vision is to be a global leader in the production of cannabis and cannabis-derived products that improve the health and well-being of its clients. The company is working to understand and serve the needs of its clients and partners, ensuring that its products, their quality and the ongoing commitment the company brings to health and well-being remain its fundamental priorities.
The AgMedica team is dedicated to the development of cannabis derived products for medical, adult-use (recreational once approved) and ultimately pharmaceutical purposes. This will be accomplished through plant and product research and development, innovative production practices, comprehensive clinical and health benefit assessments and a commitment to client value. AgMedica is committed to developing and commercializing innovative products, processes and services.
Name Change to AgMedica
AgMedica Bioscience Inc. (formerly AgriMed Botanicals Inc. or AMBI) changed its name on December 6, 2017. “Our name change to AgMedica Bioscience reflects our evolution and strategic vision to become a dominant vertically integrated player in the medical cannabis market and to invest in world-class research and development to develop and commercialize clinically-proven cannabis-derived pharmaceutical products for human and veterinary use.” said CEO, Art Vander Pol.
– 30 –
For further information:
Peter Van Mol
Chief Financial Officer